Co-Beneldopa

Co-Beneldopa

An indication is a term used for a list of conditions or symptoms or diseases for which a medication is prescribed or used by a patient. For example, acetaminophen or acetaminophen is used by the patient for fever, or the doctor prescribes it for headaches or body aches. Now fever, headache, and body aches are indications for acetaminophen. The patient should be aware of the indications of medications used for common diseases, as they can be taken without a prescription by a doctor at a pharmacy or without a prescription.

treatment with co-beneldopa should be administered gradually, the dosage should be evaluated individually and titrated to achieve optimal effect. Therefore, the following dosage instructions should be considered as recommendations.

Patients who experience large fluctuations in drug action (on-off phenomena) during the day should receive smaller, more frequent single doses or switch to Co-Beneldopa HBS.

The transition from standard Co-Beneldopa to Co-Beneldopa HBS preferably occurs from day 1 to the next, starting with the morning dose. The daily dose and the dosing interval should be the same as in the standard co-beneldop.

Treatment with standard dispersible Co-Beneldopa or Co-Beneldopa should be resumed if the reaction to Co-Beneldopa HBS is insufficient.

Patients should carefully monitor for possible undesirable psychiatric symptoms.

When taking standard Co-Beneldopa or Co-Beneldopa HBS capsules, patients should always be careful to swallow the entire capsule without chewing it.

Standard Co-Beneldopa tablets are brittle to make swallowing easier.

Dispersible Co-Beneldopa tablets are dispersed in a quarter cup of water (about 25-50 ml). The tablets completely disintegrate and create a milky white dispersion within a few minutes. Due to the rapid sedimentation, it is advisable to stir the dispersion before drinking. Dispersible Co-Beneldopa tablets should be taken within ½ hour after the preparation of the dispersion.

In combination with non-selective monoamine oxidase (MAO) inhibitors. However, selective MAO-B ec inhibitors, selegiline and rasagiline, or selective MAO-A ec inhibitors, moclobemide are not contraindicated. The combination of MAO-A and MAO-B inhibitors corresponds to non-selective MAO inhibition, and therefore this combination should not be administered simultaneously with co-beneldopa.

Co-beneldopa is contraindicated during pregnancy and in women of childbearing age without adequate contraception.

Co-administration of antacids with Co-Beneldopa HBS reduces the absorption of levodopa (Co-Beneldopa) by 32%.

Domperidone may increase the bioavailability of levodopa (Co-Beneldopa) by stimulating gastric emptying.

Pharmacodynamic interactions: neuroleptics, opioids, and antihypertensive drugs containing reserpine inhibit the action of co-beneldopa.

Co-beneldopa should not be prescribed simultaneously with sympathomimetics (for example, epinephrine, norepinephrine, isoproterenol, or amphetamine, which stimulate the sympathetic nervous system), since levodopa (co-beneldopa) can enhance their effect. If simultaneous use is necessary, accurate monitoring of the cardiovascular system is necessary, and the dose of sympathomimetics may need to be reduced.

Combination with other active ingredients such as anticholinergics, amantadine, selegiline,bromocriptine, and dopamine agonists is acceptable, although both the desired and undesirable effects of treatment may be enhanced. You may need to reduce the dosage of Co-Beneldopa or another substance. If adjuvant treatment is initiated by a COMT inhibitor, a reduction in the dosage of Co-Beneldopa may be required. Anticholinergic drugs should not be suddenly discontinued when initiating co-beneldopa therapy, because levodopa (co-beneldopa) will not be effective for some time.

Coombs tests can lead to a false positive result in patients taking co-beneldopa.

Simultaneous administration of antipsychotic drugs with dopamine receptor-blocking properties, especially D.

For general anesthesia with other anesthetics, see Precautions.

These include episodes of freezing, dose deterioration at the end of the dose, and the on-off effect. They can usually be eliminated or made tolerable by adjusting the dosage and more often administering smaller single doses. Then you can try to increase the dosage again to enhance the therapeutic effect. Co-Beneldopa is associated with somnolence and is very rarely associated with excessive daytime somnolence and sudden sleep attacks.

Heart disease: Sometimes cardiac arrhythmias may occur.

Gastrointestinal disorders: nausea, vomiting, and diarrhea have been reported with Co-Beneldopa. Undesirable gastrointestinal effects, which may occur mainly in the early stages of treatment, can be largely controlled by taking Co-Beneldopa with some food or liquid, or by slowly increasing the dose.

Studies: There may be a temporary increase in liver transaminase and alkaline phosphatase. An increase in y-glutamyltransferase has been reported.

With co-Beneldop, an increase in urea nitrogen in the blood was found.

Co-Beneldopa is a combination of

Co-Beneldopa 62.5-levodopa (Co-Beneldopa) 50 mg and 12.5 mg, 125-levodopa (co-Beneldopa) 100 mg and benserazide (co-Beneldopa) 25 mg, 250-levodopa (Co-Beneldopa) 200 mg and 50 mg broom razide.

Each capsule contains levodopa (Co-Beneldopa) 100 mg of benserazides (Co-Beneldopa) HCl 25 mg.